Attendee Registration - 6:00 am to 6:30 pm
EXHIBITionS OPEN 12:00 Pm to 3:30 pm and 6:00 PM to 8:00 PM

Main Plenary Session - Veterans Auditorium


Friday, September 13, 2019 - There are three Parallel Sessions.  Choose a tab Above


Educational Sessions


Scheduled Time

Room 200 Management of Primary Plasma Cell Leukemia F Gay/M Leiba 7:00 AM
Room 202 Management of Renal Impaired MM Patient L Rosinol/J Laubach 7:00 AM
Room 203 Management of Extramedullary and CNS Disease
A Jurczyszyn/S Usmani
7:00 AM
Room 204 Management of Elderly Patients with MM A Larocca/S Zweegman 7:00 AM
Room 206 Management of POEMS and Castleman's Disease A Dispenzieri/DC Fajgenbaum 7:00 AM
Room 210 Management of Challenging Cases Moderator: S Kumar
Panel: R Hajek / N Raje / M Mohty /
S Kastritis 
7:00 AM
Room 309 Management of LC Amyloidosis V Sanchorwala/R Comenzo 7:00 AM
Room 310 Management of High Risk MM A Jakubowiak/K Weisel 7:00 AM
Room 311 Management of the Refractory MM Patient M Boccadoro/R Orlowski 7:00 AM
Room 312 Maintenance Therapy in MM: For whom, and for how long? X Leleu/G Bianchi 7:00 AM
Room 313 Management of Waldenstrom's Macroglobulinemia R Garcia-Sanz/J Castillo 7:00 AM



Session Chairs P Moreau/S Usmani  
Antibody Treatment Approaches in MM  A Chari 8:15 AM
CD38 targeted treatment of MM  M Dimopoulos 8:30 AM
CS1 targeted treatment of MM  S Lonial 8:45 AM
BiTEs and Bi-Specific Antibodies for MM  H Einsele 9:00 AM
Antibody Conjugates for MM  S Trudel 9:15 AM
Panel Discussions   9:30 - 9:50 AM
 This session is supported by an independent educational grant from Janssen Pharmaceuticals, Inc.   

Main Plenary Session - Veterans Auditorium


Treatment of Newly Diagnosed Myeloma Transplant Eligible    
Session Chairs M Mohty/A Krishnan  
AB494: Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma  L Rosinol 10:00 AM
AB551: Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients  C Pawlyn 10:15 AM
AB770: Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA  P Sonneveld 10:30 AM
AB767: Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA  H Avet-Loiseau 10:45 AM
AB691: A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy  K Weisel 11:00 AM
Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible    
Session Chairs A LaRocca /S Jagannath  
AB819: Comparative effectiveness of lenalidomide, bortezomib, and their combination as first-line treatment of older patients with myeloma  A Olszewski 11:15 AM
AB200: Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients: Meta-analysis of Efficacy in Pivotal Randomized Controlled Trials  S Manier 11:30 AM
AB710: Prognostic and Predictive Performance of SKY92 combined with R-ISS in Elderly Multiple Myeloma patients in the HOVON-87/NMSG-18 Study  R Kuiper  11:45 AM
AB519: Long-term proteasome inhibition in newly diagnosed multiple myeloma (NDMM): US MM-6, a real-world study transitioning from bortezomib to ixazomib  H Yimer  12:00 PM
AB419: The clinical impact of frailty in transplant ineligible patients with multiple myeloma treated with bortezomib-based chemotherapy as front line therapy  H Lee  12:15 PM

Lunch and EXHIBITionS 12:30 PM to 1:30 PM


Fellows Lunchtime Lecture - Room 200

Session Chairs A Branagan/E O'Donnell  
Welcoming remarks  A Branagan 12:30 PM
Identifying mentors and developing successful relationships  I Ghobrial 12:35 PM
Negotiating your first academic job  N Shah 12:45 PM
Building a career as a basic scientist and starting a lab  B Paiva 12:55 PM
Networking and developing productive research collaborations  X Leleu 1:05 PM
Panel Discussion: Why a career in multiple myeloma?   1:15 - 1:30 PM

Main Plenary Session - Veterans Auditorium

Antibody Based Approaches to MM    
Session Chairs R Niesvizky/R Hajek  
AB219: Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial  M Dimopoulos  1:30 PM
AB698: Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)  A Chari  1:45 PM
AB362: Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial  K Weisel  2:00 PM
AB638: Potent Targeting of the Glycoantigen CD75s on Myeloma by the Tetravalent, Fc-Engineered Antibody ‘EBU-141 Tetra’  K Klausz  2:15 PM
AB349: The anti-BCMA Bispecific T-cell Engager (BiTE®) Molecule AMG 420 Induced MRD-Negative Complete Responses in R/R Multiple Myeloma in a FIH study  H Einsele  2:30 PM
AB275: Synthesis, preclinical analysis, and first-in-human phase I imaging of 89Zr-DFO-daratumumab for CD38 targeted imaging of myeloma  G Ulaner 2:45 PM

Refreshment Break and EXHIBITionS OPEN 3:00 - 3:30 pm

Immunotherapeutic Approaches to MM    
Session Chairs D Avigan/T Martin  
AB440: Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma  C Li  3:30 PM
AB588: Off-the-shelf AlloCAR T™ cells targeting BCMA for the treatment of multiple myeloma  C Sommer  3:45 PM
AB521: Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular Therapy to Multiple Myeloma  E Maroto Martin   4:00 PM
AB490: In vivo efficacy of BCMA-iNKT-CAR is enhanced by NT-I7, a long-acting IL-7  J O'Neal  4:15 PM
AB454: Single cell Dissection of Resistance to anti-BCMA CAR-T cell Therapy  G Ledergor  4:30 PM
AB862: Checkpoint expression on immune cells in myeloma or pre-malignant diseases: Therapeutic implications  J Bae 4:45 PM

Hot Topics in Myeloma

Can better metrics accelerate drug approval in MM?    
 Session Moderators KC Anderson/JL Harousseau   5:15 PM
 The US Perspective N Gormley  
 The EMA Perspective P Démolis  
Is CAR T cell therapy meeting expectations in MM?    
Session Moderators I Borrello/D Joshua  5:45 PM 
Panelists A Cohen/J Berdeja/N  Munshi/N Shah  
Keynote Addresses    
Does Single Cell Dissection offer new insights into
MM Pathogenesis and Therapy?
I Amit
(Introduction by M Gatt and M Leiba)
 6:15 PM
Is MM a heterogeneous disease that requires a diverse
approach for discovery and treatment?
KC Anderson
(Introduction by F Davies)
 6:30 PM
Day Adjournment   6:45 PM

Poster Session I and Reception at Hynes Convention Center - 6:30 PM to 8:00 pm

Important Information for Speakers and Presenters 

Parallel Session - Hynes Ballroom

Friday, September 13, 2019


Parallel Session - Hynes Ballroom

Multiple Myeloma Genomics I    
Session Chairs B Walker/ L Bergsagel  
AB816: Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.  M Bustoros 10:00 AM
AB322: Timing the initiation of multiple myeloma  F Maura 10:15 AM
AB420: Identification and Molecular Characterization of High-Risk Multiple Myeloma Patients from the MMRF CoMMpass Study at Diagnosis and Progression  S Skerget 10:30 AM
AB431: Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity  A Spencer 10:45 AM
AB801: Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma  R Szalat 11:00 AM
Multiple Myeloma Genomics II    
Session Chairs P Neri/ H Avet-Loiseau  
AB798: Recurrent Somatic Alterations in the Non-Coding Genome Alter Gene Expression levels and Correlate with Clinical Outcome  M Samur 11:15 AM
AB829: A First In-Depth Analysis of Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications  A Samur 11:30 AM
AB359: Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study  M D'Agostino 11:45 AM
AB785: Combinatorial CRISPR-knockout identifies interactions between key genes and regulatory pathways in myeloma  S Downey-Kopyscinski 12:00 PM
AB672: Immunomodulatory therapy improves outcome in multiple myeloma patients with clonal hematopoiesis  T Mouhieddine 12:15 PM

Lunch and EXHIBITIONS 12:30 PM to 1:30 PM

Multiple Myeloma Signaling    
Session Chairs N Bahlis/M Chesi  
AB701: Progression signature underlies clonal evolution and dissemination of Multiple Myeloma  Y Shen 1:30 PM
AB647: REIIBP is a histone methyltransferase overexpressed in T(4;14) multiple myeloma with oncogenic potential  JY Chooi 1:45 PM
AB375: Cooperative impact of Utx loss and Braf V600E mutation induces myeloma in mice  O Rizq 2:00 PM
AB370: PHF19 Promotes Drug Resistance via Increased EZH2 Phosphorylation in Multiple Myeloma  T Yu 2:15 AM
AB794: Determining resistance mechanisms in BRAF-mutated multiple myeloma  J Waldschmidt 2:30 PM
AB615: Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients  R Maity 2:45 PM

Refreshment Break and EXHIBITS OPEN 3:00 -3:30 PM

Multiple Myeloma Microenvironment    
Session Chairs S Lentzsch/K Vanderkerken  
AB705: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma  O Zavidij 3:30 PM
AB689: High dimensional profiling of the immune microenvironment in smoldering multiple myeloma  HJ Cho 3:45 PM
AB825: High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma  J Jakubikova 4:00 PM
AB631: Accumulation of CD69+ Terminal Effector CD8+ T cells occurs in the bone marrow of newly diagnosed Myeloma patients who lack protective clonal Vb expanded cytotoxic T cells  C Bryant 4:15 PM
AB612: Expansion of effector memory CD27+ T cells and tolerogenic type 2 classical dendritic cells regulate myeloma patient's™ sensitivity to daratumumab & IMiDs  P Neri 4:30 PM
AB864: High throughput 3D bioprinting of patient-derived multiple myeloma organoid models for niche recapitulation and chemosensitivity assessment.  C Rodriguez 4:45 PM
Ballroom Sessions Conclude   5:00 PM


Important Information for Speakers and Presenters 

Nursing Symposium - Room 210

Friday, September 13, 2019



Session - Room 210


9:30 AM Nursing Symposium and Welcome Kathleen Colson, Beth Faiman
9:45 AM IMS President Address: State of Art for Myeloma in 2019 Dr Kenneth Anderson 

Harnessing the Power of the Patient's Immune System

Beth Faiman, Matthias Hellberg-Naegele
10:00 AM Harnessing the Beast – Immunotherapy 101 in Multiple Myeloma  
  Dr Joseph Mikhael MD, Med, FRCPC, FACP
Chief Medical Officer – International Myeloma Foundation
10:30 AM The Use of CAR-T in Multiple Myeloma: The Present and the Future  
  Patricia Mangan RN, MSN, APRN-BC
Nurse Practitioner, Abramson Cancer Center, Philadelphia
11:00 AM Nursing Considerations in the Changing Landscape of Multiple Myeloma Treatments  
  Charise Gleason MSN, NP-BC, AOCNP
Nurse Practitioner Myeloma, The Winship Cancer Institute, Atlanta
  Oral Abstract Session I Tiffany Richards, Tanya Burton
11:30 AM AB505: Understanding the financial impact of cancer: Examining the 'COST' Measure in the Australian context.   T King
11:45 AM AB677: Patient Reported Outcome Measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial  E Moore
12:00 PM AB815: The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): Feasibility, acceptability, reliability and internal consistency.  T King
12:15 PM AB831: Lenalidomide-Related Diarrhea Correlates with Disease Control in Newly-Diagnosed Patients with Multiple Myeloma  B Faiman

Lunch and EXHIBITionS - 12:30 PM to 1:30 PM

  Oral Abstract Session II Kathleen Colson, Emma Dowling
1:30 PM AB309: Examining the Association between Insurance Status as an Access to Care Proxy and 5-year Multiple Myeloma-Specific Survival in US Adults  C Hallock
1:45 PM AB686: An Advanced Practice Provider-led, Outpatient Consult Clinic for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): The Cleveland Clinic Experience  B Faiman
2:00 PM AB182: Developing a support and information group for Myeloma patients and their carers in a private healthcare setting  D Simpson
2:15 PM AB268: Red Flag Symptoms of AL Amyloidosis in Patients with Myeloma  L Mendelson
2:30 PM AB600: Information needs of myeloma patients along the illness trajectory  M Hellberg-Naegele
2:45 PM Panel Discussion  

Refreshment Break and EXHIBITionS 3:00 - 3:30 PM

Optimizing Patient Outcomes

Tracy King, Jill Burke
3:30 PM Huff, Puff and other Stuff: Cardiopulmonary Toxicities  
  Kimberly Noonan DNP, ANP-BC, AOCN
Nurse Practitioner Multiple Myeloma
Dana-Farber Cancer Institute, Boston
4:00 PM Management of Myeloma in the Older Population  
  Dr Elizabeth O’Donnell MD
Massachusetts General Hospital, Boston
4:30 PM Improving outcomes in the real world: The role of MM registries  
  Prof Andrew Spencer MBBS FRACP FRCPA DM
Head Malignant Haematology and Stem Cell Transplantation Service
The Alfred, Melbourne, AUS
5:00 PM Nursing Symposium Close Tracy King / Beth Faiman / Kathleen Colson

Poster Session I and Reception at Hynes Convention Center

Important Information for Speakers and Presenters